These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

180 related items for PubMed ID: 9285556

  • 1. Mutations of critical amino acids affect the biological and biochemical properties of oncogenic A-Raf and Raf-1.
    Bosch E, Cherwinski H, Peterson D, McMahon M.
    Oncogene; 1997 Aug 28; 15(9):1021-33. PubMed ID: 9285556
    [Abstract] [Full Text] [Related]

  • 2. Development of a conditional in vivo model to evaluate the efficacy of small molecule inhibitors for the treatment of Raf-transformed hematopoietic cells.
    Konopleva M, Shi Y, Steelman LS, Shelton JG, Munsell M, Marini F, McQueen T, Contractor R, McCubrey JA, Andreeff M.
    Cancer Res; 2005 Nov 01; 65(21):9962-70. PubMed ID: 16267021
    [Abstract] [Full Text] [Related]

  • 3. Differential abilities of activated Raf oncoproteins to abrogate cytokine dependency, prevent apoptosis and induce autocrine growth factor synthesis in human hematopoietic cells.
    McCubrey JA, Steelman LS, Hoyle PE, Blalock WL, Weinstein-Oppenheimer C, Franklin RA, Cherwinski H, Bosch E, McMahon M.
    Leukemia; 1998 Dec 01; 12(12):1903-29. PubMed ID: 9844921
    [Abstract] [Full Text] [Related]

  • 4. Conditionally oncogenic forms of the A-Raf and B-Raf protein kinases display different biological and biochemical properties in NIH 3T3 cells.
    Pritchard CA, Samuels ML, Bosch E, McMahon M.
    Mol Cell Biol; 1995 Nov 01; 15(11):6430-42. PubMed ID: 7565795
    [Abstract] [Full Text] [Related]

  • 5. Regulation of A-raf expression.
    Lee JE, Beck TW, Wojnowski L, Rapp UR.
    Oncogene; 1996 Apr 18; 12(8):1669-77. PubMed ID: 8622887
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Rapid phosphorylation of Ets-2 accompanies mitogen-activated protein kinase activation and the induction of heparin-binding epidermal growth factor gene expression by oncogenic Raf-1.
    McCarthy SA, Chen D, Yang BS, Garcia Ramirez JJ, Cherwinski H, Chen XR, Klagsbrun M, Hauser CA, Ostrowski MC, McMahon M.
    Mol Cell Biol; 1997 May 18; 17(5):2401-12. PubMed ID: 9111309
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Autophosphorylation modulates the kinase activity and oncogenic potential of the Met receptor tyrosine kinase.
    Rodrigues GA, Park M.
    Oncogene; 1994 Jul 18; 9(7):2019-27. PubMed ID: 8208547
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Correlation of constitutive activation of raf-1 with morphological transformation and abrogation of tyrosine phosphorylation of distinct sets of proteins in human squamous carcinoma cells.
    Patel BK, Ray S, Whiteside TL, Kasid U.
    Mol Carcinog; 1997 Jan 18; 18(1):1-6. PubMed ID: 9022807
    [Abstract] [Full Text] [Related]

  • 14. Structural and functional domains critical for constitutive activation of the HGF-receptor (Met).
    Zhen Z, Giordano S, Longati P, Medico E, Campiglio M, Comoglio PM.
    Oncogene; 1994 Jun 18; 9(6):1691-7. PubMed ID: 8183564
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. v-Rel and c-Rel are differentially affected by mutations at a consensus protein kinase recognition sequence.
    Mosialos G, Gilmore TD.
    Oncogene; 1993 Mar 18; 8(3):721-30. PubMed ID: 8437855
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.